PHARMX TECHNOLOGIES LIMITED — Board/Management Information 2020

Apr 15, 2020

16 April 2020

==> picture [136 x 91] intentionally omitted <==

Market Release

Julian Sallabank Joins Corum Board

Corum Group Limited (ASX:COO) is pleased to announce that Julian Sallabank has accepted an appointment to the Corum Group Board of Directors.

Julian brings to Corum vast experience in senior executive and Board roles for both private and ASX listed companies operating in the medical technology and recruitment sectors.

Primary areas of expertise are strategic planning, commercialisation and organisational development of both domestic and international businesses.

Julian is currently Managing Director of a privately owned early stage medical research impact and innovation Fund. The Fund collaborates with the Murdoch Children’s Research Institute and has developed a varied portfolio including Therapeutics, Diagnostics and Digital Health.

Previously Julian held roles as Chief Executive Officer of ASX listed Ignite Limited (ASX:IGN) which provides specialist recruitment and on demand information technology services and Student Edge, Australia’s largest student membership organisation.

Julian Sallabank said, “I am delighted to join the Corum Board at this exciting time for the Company. I look forward to contributing to Corum’s growth in its core pharmacy software market and creating new opportunities in related technologies.”

Corum Group Chairman Nick England said, “We are extremely pleased that Julian has agreed to join the Corum Board. His experience will assist Corum in pursuing and achieving its growth aspirations.”

For further information contact: David Clarke, Managing Director Investor email: companysecretary@corum.com.au

Corum Group Limited | ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 PO Box Q281, Queen Victoria Building NSW 1230 T 02 9289 4699 | F 02 9299 3276 | www.corumgroup.com.au